A phase II trial of marimastat in advanced pancreatic cancer.

Evans, J; Stark, A; Johnson, C; Daniel, F; Carmichael, J; Buckels, J; Imrie, C; Brown, P; Neoptolemos, J

Journal article

A phase II trial of marimastat in advanced pancreatic cancer.

Abstract:: Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer. A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14). Patients with a response to treatment could continue marimastat beyond 28 days. Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment. The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study. There were 31 patients (27%) who required dose modification. Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9. Of 83 patients with radiologically assessable disease, 41 (49%) had stable disease. The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9. The overall survival was 3.8 months. 5.9 months for stage II, 4.7 months for stage III and 3 months for stage IV disease. Of 90 patients, 46 (51%) had stabilization or reduction in pain, mobility and analgesia scores. Further development and clinical evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted.

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Evans, J., Stark, A., Johnson, C., Daniel, F., Carmichael, J., Buckels, J., Imrie, C., Brown, P., & Neoptolemos, J. (2001). A phase II trial of marimastat in advanced pancreatic cancer. British Journal of Cancer, 85(12), 1865–1870.

MLA Style

Evans, J, et al. “A Phase II Trial of Marimastat in Advanced Pancreatic Cancer.” British Journal of Cancer, vol. 85, no. 12, 2001, pp. 1865–70.

Chicago Style

Evans, J, A Stark, C Johnson, et al. 2001. “A Phase II Trial of Marimastat in Advanced Pancreatic Cancer.” British Journal of Cancer 85 (12): 1865–70.
Print